/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was...
New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually...
BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency – – Preliminary...